Polaris lung cancer clinical trial phase III analysis reached the highest standard, and drug certification is imminent
Polaris Group (TW:6550) released its interim analysis report for the Phase III clinical trial of pleural mesothelioma (a type of lung cancer) in the United States on February 25 (U.S. time).